18889881171
Kalkine 0
countryflagUS
Kalkine Login

AAPL 222.73 -0.4559% MSFT 391.955 -0.8111% NVDA 113.445 -6.003% GOOGL 166.905 -2.1429% GOOG 169.12 -2.124% AMZN 202.04 -1.7841% META 610.7313 -2.4874% AVGO 178.775 -5.0382% LLY 835.66 -1.9581% TSLA 270.5301 -6.1116% TSM 172.12 -4.8535% V 344.51 -0.0319% JPM 251.71 0.231% UNH 517.57 0.8063% NVO 72.16 -1.9565% WMT 84.78 0.0236% LVMUY 128.17 -0.7588% XOM 118.245 1.4195% LVMHF 638.0 -1.6131% MA 548.525 0.6172%

Sirona Biochem Corp

Healthcare US SRBCF

0.0208USD
0.0075(56.39%)

Last update at 2025-03-25T20:00:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.050.15
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap19.17M
  • Volume60000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.06504M
  • Revenue TTM0.08M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.62M
  • Diluted EPS TTM-0.01

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Income before tax -3.55185M -2.31202M -4.14080M -4.55578M -1.15314M
Minority interest - - - - 0.00000M
Net income -3.55780M -2.30633M -4.13372M -4.54957M -1.27325M
Selling general administrative 2.67M 1.08M 2.60M 2.86M 1.02M
Selling and marketing expenses - - - - -
Gross profit 0.67M 0.27M 0.11M 0.14M 1.28M
Reconciled depreciation 0.00909M 0.00946M 0.00970M - 0.00000M
Ebit -3.53127M -2.28858M -4.12927M -4.19879M -0.85627M
Ebitda -3.52218M -2.27913M -4.11958M -4.44355M -0.91198M
Depreciation and amortization 0.00909M 0.00946M 0.00970M - -
Non operating income net other - - - - 0.00000M
Operating income -3.53127M -2.28858M -4.12927M -4.44355M -0.91198M
Other operating expenses 4.21M 2.56M 4.28M 4.60M 2.22M
Interest expense 0.03M 0.00333M 0.01M 0.12M 0.23M
Tax provision 0.00595M -0.00568M -0.00708M -0.00621M 0.12M
Interest income - - 0.04M - -
Net interest income -0.02700M -0.00333M 0.03M -0.11674M -0.22677M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.00595M -0.00568M -0.00708M -0.00621M 0.12M
Total revenue 0.67M 0.27M 0.11M 0.14M 1.28M
Total operating expenses 4.21M 2.56M 4.28M 4.60M 2.22M
Cost of revenue - - - - 0.06M
Total other income expense net 0.01M -0.01187M 0.00160M 0.03M 0.02M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -3.55780M -2.30633M -4.13372M -4.54957M -1.27325M
Net income applicable to common shares -3.55780M -2.30633M -4.13372M -4.54957M -1.27325M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Total assets 1.29M 1.29M 2.14M 4.26M 0.77M
Intangible assets - - - - 0.00000M
Earning assets - - - - -
Other current assets - - - - 0.00000M
Total liab 1.08M 1.38M 2.09M 2.07M 3.03M
Total stockholder equity 0.21M -0.09702M 0.05M 2.19M -2.26097M
Deferred long term liab - - - - 0.00000M
Other current liab 0.18M 0.11M 0.11M 0.10M 0.15M
Common stock 34.49M 31.21M 29.08M 28.52M 20.40M
Capital stock 34.49M 31.21M 29.08M 28.52M 20.40M
Retained earnings -41.35757M -37.79976M -35.49343M -31.35971M -26.81013M
Other liab 0.12M 0.13M 0.12M 0.10M 0.08M
Good will - - - - 0.00000M
Other assets - - - - 0.00000M
Cash 0.42M 0.78M 1.54M 3.73M 0.34M
Cash and equivalents - - - - -
Total current liabilities 0.86M 0.74M 1.03M 0.92M 1.86M
Current deferred revenue - - - - -
Net debt 0.05M 0.07M -0.29399M -2.18594M 2.17M
Short term debt 0.37M 0.34M 0.30M 0.50M 1.41M
Short long term debt 0.34M 0.30M 0.26M 0.47M 1.38M
Short long term debt total 0.47M 0.85M 1.24M 1.55M 2.51M
Other stockholder equity 7.31M 6.55M 6.56M 5.06M 4.19M
Property plant equipment 0.02M 0.03M 0.04M - 0.00000M
Total current assets 1.27M 1.26M 2.10M 4.26M 0.77M
Long term investments - - - - 0.00000M
Net tangible assets 0.21M -0.09702M 0.05M 2.19M -2.26097M
Short term investments - - - 0.00073M 0.00074M
Net receivables 0.80M 0.44M 0.50M 0.46M 0.30M
Long term debt 0.09M 0.47M 0.85M 0.94M 0.96M
Inventory - - - - 0.00000M
Accounts payable 0.32M 0.30M 0.62M 0.31M 0.29M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income -0.22413M -0.05771M -0.10154M -0.03369M -0.03882M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other - - - 0.00000M 0.00000M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 0.02M 0.03M 0.04M 0.00000M 0.00000M
Capital lease obligations 0.04M 0.08M 0.13M 0.14M 0.18M
Long term debt total - - - - 0.00000M
Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Investments - - -0.04697M - 0.00000M
Change to liabilities 0.09M -0.29469M 0.41M 0.06M -0.02169M
Total cashflows from investing activities - - -0.04697M -0.04697M -0.04697M
Net borrowings -0.33837M -0.30826M -0.13338M -0.24060M -0.21972M
Total cash from financing activities 2.04M 1.45M -0.04596M 6.96M 0.72M
Change to operating activities -0.02262M 0.05M 0.02M 0.09M -0.02269M
Net income -3.55780M -2.30633M -4.13372M -4.54957M -1.27325M
Change in cash -0.35649M -0.75787M -2.19877M 3.40M 0.07M
Begin period cash flow 0.78M 1.54M 3.73M 0.34M 0.27M
End period cash flow 0.42M 0.78M 1.54M 3.73M 0.34M
Total cash from operating activities -2.17751M -2.15823M -2.11210M -3.55949M -0.65380M
Issuance of capital stock - - 0.00000M 3.14M 0.60M
Depreciation 0.00909M 0.00946M 0.00970M -0.08622M -0.11445M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables -0.36043M 0.05M -0.03450M -0.14538M 0.41M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 2.38M 1.76M 0.09M 4.07M 0.12M
Change to netincome 1.67M 0.34M 1.62M 0.99M 0.32M
Capital expenditures 0.00000M 0.00000M 0.05M 0.05M 0.05M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -0.29548M -0.19844M 0.39M 0.00046M 0.36M
Stock based compensation 1.46M 0.33M 1.62M 1.06M 0.12M
Other non cash items 0.20M - 0.00246M -0.06112M 0.13M
Free cash flow -2.17751M -2.15823M -2.15907M -3.55949M -0.65380M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SRBCF
Sirona Biochem Corp		 0.0075 56.39% 0.02 - - 246.53 36.93 258.54 -9.9766
NVO
Novo Nordisk A/S		 -1.44 1.96% 72.16 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.28 1.75% 72.07 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.84 1.54% 501.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.08 0.01% 634.22 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

Sirona Biochem Corp

595 Burrard Street, Vancouver, BC, Canada, V7X 1L4

Key Executives

Name Title Year Born
Dr. Howard J. Verrico M.D., Ph.D. Founder, Chairman, CEO & Sec. 1961
Mr. Christopher D. Hopton C.G.A., C.P.A. CFO & Director 1966
Dr. Géraldine Deliencourt-Godefroy Ph.D. Chief Scientific Officer & Director NA
Ms. Michelle Seltenrich MBA VP of Operations NA
Dr. Brett A. Premack Ph.D. Scientific Consultant NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.